基本信息
views: 182
Career Trajectory
Bio
His primary focus clinically is therapy of advanced lung cancer. He has published more than 310 peer-reviewed papers, and edited the text Lung Cancer: Prevention, Management and Emerging Therapies published in 2010. His primary area of research interest is personalization of therapy using tools that include phase I and II clinical trials, studies of plasma pharmacokinetics and tumor and normal tissue uptake of chemotherapy agents, resistance mechanisms, resistance modulation, and host single nucleotide polymorphisms and tumor biomarkers that correlate with treatment outcome and prognosis. He also has a major interest in and concern for issues impeding cancer clinical research, with publications that have included (among others) Cancer: the road to Amiens (Journal of Clinical Oncology 27(3):328-33, 1/2009), Equipoise lost: ethics, costs and the regulation of cancer clinical research (Journal of Clinical Oncology 28(17):2925-35, 2010), Fool’s gold, lost treasures and the randomized clinical trial (BMC Cancer 2013 Apr;13(1):193),and Redefining cancer: a new paradigm for better and faster treatment innovation. J Popul Ther Clin Pharmacol 2014 Feb 23; 21(1):e56-e65).
Research Interests
Papers共 377 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CURRENT ONCOLOGYno. 5 (2024): 2453-2480
The oncologist (2024)
The oncologist (2024)
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 8 (2024): 973-974
Current Oncologyno. 7 (2024): 3738-3751
CURRENT ONCOLOGYno. 3 (2024): 1600-1617
Current oncology (Toronto, Ont.)no. 9 (2023): 8310-8327
crossref(2023)
Elsevier eBookspp.57-78, (2023)
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 384
#Citation: 12542
H-Index: 55
G-Index: 100
Sociability: 7
Diversity: 1
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn